The neuroleptic/dopamine receptor, with its picomolar affinity for potent neuroleptics, is the functional dopamine receptor of the brain. This receptor has been termed the D 2 dopamine receptor, and it inhibits or interferes with dopamine-stimulated adenylate cyclase. This D 2 receptor has two states, each having different affinity for dopamine. The high-affinity state, termed D 2 hlg , has a 10 nM affinity for dopamine and is the functional correlate for dopamine autoreceptors and for the dopamine receptor in the pituitary gland. The low-affinity state, termed D 2 ' ow , has a 2000 nM affinity for dopamine, and may possibly represent the desensitized state of the dopamine receptor or the functional post-synaptic receptor. RESUME: Le recepteur neuroleptique/dopamine, avec son affmite picomolaire pour les neuroleptiques puissants, est le recepteur dopaminergique fonctionnel du cerveau. Ce recepteur fut appele le recepteur dopaminergique D 2 ; il inhibe ou interfere avec l'adenylate cyclase stimulee par la dopamine. Ce recepteur D 2 gh , a une affmite a 10 nM pour la dopamine et correspond a l'etat fonctionnel des autorecepteurs dopaminergiques et des recepteurs dopaminergiques de la glande pituitaire. L'etat de basse affmite, D 2 low , a une affmite a 2000 nM pour la dopamine, et represente probablement l'etat desensibilise du recepteur dopaminergique.
Definition of a dopamine receptor
A neurotransmitter receptor is a membrane-located protein which when stimulated by the transmitter results in an electrical or chemical effect. A receptor should be affected by drug doses or concentrations which correlate with the drug doses or concentrations causing a particular brain response subserved by that receptor.
A dopamine receptor is defined as that receptor which is more sensitive to dopamine than to any other neurotransmitter. Thus, the primary criterion of a dopamine receptor is that it be most sensitive to dopamine, less sensitive to noradrenaline and even less sensitive to serotonin. If one includes exogenous drugs, such as bromocriptine, apomorphine and ADTN (6, 7-dihydroxy-2-aminotetralin), a dopamine receptor is defined as one which has the following rank order of dopaminergic agonist potencies:
Bromocriptine > apomorphine = ADTN > dopamine > noradrenaline > serotonin A dopamine receptor and a "dopaminergic site" generally have the same rank order of sensitivities to dopamine agonists; a dopamine receptor, however, has a functional correlate, while the functional correlate of a "dopaminergic site" is one which rejnains to be established.
Classification of central and peripheral dopaminergic sites and receptors
Subclassification of the dopaminergic sites (and/or states) depends on the absolute molarities of agonists and antagonists to which the sites are sensitive. Thus, the nomenclature used in this laboratory is based solely on the absolute sensitivities of the site to three drugs: dopamine, spiperone and sulpiride. This is summarized in Table I and Fig. I .
The sites and/or states (in Table 1 ) are defined according to two criteria: A) by the order of magnitude of the absolute molarities (uM or nM) of dopamine and spiperone that were 50% effective in vitro; and B) by whether or not the site was sensitive to R-sulpiride of S-sulpiride.
Dopamine-stimulated adenylate cyclase, or the D, site:
Dopamine-stimulated adenylate cyclase, first detected in 1972 by Kebabian et al., has been termed the D| site (Kebabian and Calne, 1979) . The D t site is sensitive to micromolar concentrations of dopamine as well as to micromolar concentrations of spiperone, As explained in the test, we had previously used the term " D 4 " instead of D 2 h1gh because we were not sure that all the D 2 h ' 8h sites could be converted to D 2 low sites (Wreggett and Seeman, 1983a, b but is extremely insensitive to the substituted benzamides, such as sulpiride or metoclopramide (Refs. in Seeman, 1980) . These properties thus define the Di site for any tissue response or for the competition for the binding of any 
The neuroleptic/dopamine receptor, or the D 2 dopamine receptor:
The neuroleptic/dopamine receptor, having much higher affinity and selectivity than the D| site for all neuroleptics, was first detected in 1975 by Seeman et al. (1975a, b) . This receptor has been termed the D 2 dopamine receptor, as suggested by Spano (see Kebabian and Calne, 1979) . The D 2 dopamine receptor inhibits adenylate cyclase in the anterior pituitary gland (De Camilli et al., 1979) and in the intermediate lobe of the pituitary (Meunier et al., 1980; Cote et al., 1981) . There is good (but indirect) evidence for a similar type of inhibition in the brain striatum (Stoof and Kebabian, 1981) . Fig. 2 (Stoof and Kebabian, 1981) . The D 2 interference may be via a G, protein, as is the case in the pituitary gland (Meunier etal., 1980 : Cote el al., 1981 . Dopamine autoreceptors are sensitive to very low concentrations of dopamine (nanomolar) and thereby inhibit the release of dopamine from the nerve terminals.
dopaminergic behaviours (rotation, locomotion, anti-Parkinson action, psychotomimetic action, emesis and stereotypy), as exemplified in Fig. 3 (Seeman, 1980) . The D 2 dopamine receptor is experimentally characterized by its picomolar affinity for spiperone (an antagonist), and by having both nanomolar and micromolar affinity states for dopamine itself. Since spiperone recognizes both the D 2 h,gh and the D 2 ' ow states with equal affinity (60 pM), radioactive hlgh state is sensitive to about 10 nM dopamine, while the D 2 low state is sensitive to approximately 2000 nM dopamine, these values being most readily apparent in the absence of NaCl.
The proportion of D 2 receptors in the high and low affinity states can be regulated by sodium ions (see Fig. 5 ), and by guanine nucleotides (Zahniser and Molinoff, 1978; Sibley etal., 1982) .
Up until now it has not been possible to convert all the brain D 2 hlgh sites into D 2 ' ow sites by means of high concentrations of guanine nucleotides (see Huff and Molinoff, 1982; Wreggett et al., 1982; Wreggett and Seeman, 1983a, b) . A complete conversion has been found for D 2 receptors in anterior pituitary tissue Sibley et al., 1982) , but not until now for brain tissue.
Figs. 5 and 6 illustrate for the first time a complete conversion of D 2 hlgh into D 2 ' ow in brain tissue. This conversion occurred at 37° in the presence of NaC 1 and a guanine nucleotide, and could only be demonstrated if allowance was made for the fact that 3 H-spiperone also labelled serotonin S 2 receptors in the rat brain striatum (List and Seeman, 1981; Wreggett and Seeman, 1983a, b) . Seeman (1980 (Fig. 5) was done in the presence of 50 nM ketanserin which served to occlude as much as possible the serotonin sites from becoming occupied by 3 H-spiperone (see also List and Seeman, 1981; Wreggett and Seeman, 1983a, b) .
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Figure 3 -The clinical doses for anti-Parkinson action correlate with the IC sn values for s H-spiperone at D 2 dopamine receptors. The doses of dopamine agonists which elicit contralateral turning (in 6-hydroxy-dopamine-lesioned rats unilaterally lesioned in the substantia nigra) correlate with the ICsn values for these dopamine agonists on ^H-spiperone binding to D 2 dopamine receptors. Further details and references in
The third phase, affected by 10~5 to 10" 4 M dopamine, represents the displacement of 3 H-spiperone by dopamine at a serotonin receptor or site. This was shown by separate experiments where under conditions when all the D 2 receptors were selectively blocked (by 10 u,M S-sulpiride), it was found that serotonin much more effectively inhibited (at 10~* 5 M) the binding of 3 H-spiperone than did dopamine (10~4M). Thus, in the range between 10~5M and 10~4M, dopamine inhibits the binding of 3 H-spiperone to serotonin receptors. In other words, 50 nM ketanserin (in Fig. 5 ) was insufficient to occlude the serotonin sites from being occupied by 3 H-spiperone. As Fig. 5 illustrates, dopamine inhibited the binding of 3 H-spiperone in three phases in the absence of NaCl, two of there phases being associated with the dopamine receptor, as mentioned above. In the presence of both NaCl and guanine nucleotide, however, dopamine exhibited two phases for the inhibition of 3 H-spiperone, one phase representing a single population of dopamine receptors completely in the D 2 low state, and the other phase representing a single population of serotonin receptors. Fig. 6 also illustrates conversion in the presence of both NaCl and a guanine nucleotide. The example shown is for ADTN which inhibited the binding of 3 H-spiperone in three phases, the D 2 h ' 8h phase having a K D of 3.4 nM and the D 2 low phase having a K D of 155 nM, and where the proportions of dopamine receptors in the high-and low-affinity phases were about equal (in the absence of NaCl). Although 50 nM ketanserin was used to occlude the serotonin sites, ADTN did displace 3 H-spiperone from a third site, the serotonin sites. ADTN recognized these sites at p.M concentrations.
In the presence of NaCl (Fig. 6) , many of the D 2 hlgh sites were converted into the D 2 ' ow state, since ADTN recognized 
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•4- We have previously used the term "D 4 " to denote D2 hlgh (Seeman, 1980) , because it was then not possible to know whether all the D 2 hlgh sites could be converted into the D2 low state. Thus, D 4 was a term that could be applied to conversion-resistant D 2 sites. Fig. 5 , however, indicates that complete conversion does occur in brain tissue, and, thus, there is no longer any need to use the D 4 nomenclature.
The D 3 dopaminergic site:
The D 3 dopaminergic site is defined by its high affinity (nM) for dopamine and its low affinity (uM) for neuroleptics (List et al., 1979 (List et al., , 1980 Sokoloffetal., 1980) . The rank order of potencies of the dopaminergic congeners at the D 3 site generally follows that for the D 2 sites, with one important exception: bromocriptine is particularly weak at the D 3 site.
There is as yet no known functional correlate of the D 3 site. Creese (1981) has suggested that it may be a different state of the D| site. Certainly this would be consistent with the fact that bromocriptine is weak at both the Di and D 3 sites.
Earlier work had suggested that the D 3 site was located on the nigrostriatal dopamine neurones since the density of these D 3 sites, as detected by 3 H-dopamine binding, were reduced in the putamen and caudate nucleus in Parkinson's disease (Lee et al., 1981 Rusterholz et al., Goodale et al., andR.P. Long References in Seeman, 1980) . The IC 50 values are the concentrations which 50% inhibited the specific binding to calf brain striatum (Seeman, 1980) . Adapted from Seeman (1980) , which contains further details and chemical structures of the agonists.
